Tyr723
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Tyr723 - Kit (mouse)

Site Information
SCDSSNEyMDMKPGV   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: Kit (human): Y721, Kit (rat): (Y722)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448017
Additional spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (16), flow cytometry (15), immunoprecipitation (15), mass spectrometry (3, 4, 5, 6, 9, 10, 11, 12), mutation of modification site (8, 14, 15, 16), phospho-antibody (7, 13, 14, 15, 16), western blotting (7, 13, 15)
Disease tissue studied: testicular cancer (3, 5)
Relevant cell line - cell type - tissue: 32D (myeloid) (15), BaF3 ('B lymphocyte, precursor') (8, 14), COS (fibroblast) (16), F9 (testicular) (3), IC2 (mast) (13), mast-bone marrow (8), mast-bone marrow [PTPRA (mouse), homozygous knockout] (7), P19 (testicular) (5), PYS-2 (epithelial) (6)

Controlled by
Treatments: bortezomib (2), SCF (7, 8, 13, 14, 16), SU6656 (7)

Downstream Regulation
Effects of modification on Kit: molecular association, regulation (14, 15, 16), phosphorylation (8)
Effects of modification on biological processes: cell cycle regulation (8, 14, 15)
Induce interaction with: PIK3R1 (mouse) (14, 15, 16)


References

1

Zhang H, et al. (2014) Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr Biol 24, 2501-8
25438940   Curated Info

2

Liu S, et al. (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17, 333-47
20385359   Curated Info

3

(2010) CST Curation Set: 9105; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

4

(2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

5

(2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

6

(2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

7

Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415   Curated Info

8

Yu M, et al. (2006) The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281, 28615-26
16873377   Curated Info

9

(2006) CST Curation Set: 1516; Year: 2006; Biosample/Treatment: cell line, Thom/serum starved; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

(2006) CST Curation Set: 1517; Year: 2006; Biosample/Treatment: cell line, Thom/serum starved; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

(2006) CST Curation Set: 1518; Year: 2006; Biosample/Treatment: cell line, Thom/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

(2006) CST Curation Set: 1519; Year: 2006; Biosample/Treatment: cell line, Thom/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Shivakrupa R, Bernstein A, Watring N, Linnekin D (2003) Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63, 4412-9
12907613   Curated Info

14

Hashimoto K, et al. (2003) Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101, 1094-102
12393643   Curated Info

15

Gommerman JL, et al. (2000) Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 96, 3734-42
11090054   Curated Info

16

Serve H, Hsu YC, Besmer P (1994) Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269, 6026-30
7509796   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.